Related Experiment Video
Updated: Jan 14, 2026

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
Published on: August 14, 2019
Medical Therapy for Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms
Alexis E Te1, Ashwin Ramaswamy1, Steven A Kaplan1
1Department of Urology, The Icahn School of Medicine At Mount Sinai, 1 Gustave L. Levy Place, Box 1272, New York, NY 10029 USA.
None:
Benign prostatic hyperplasia (BPH) affects the majority of aging men, with medical therapy representing the first-line treatment of lower urinary tract symptoms (LUTS). This article comprehensively examines current medical therapies, their mechanisms, efficacy, and optimal patient selection strategies through a literature review of pivotal clinical trials, systematic reviews, and treatment guidelines from 2000 to 2024. Medical therapy for BPH/LUTS has evolved from symptom management to disease modification, and combination therapy with alpha-1 adrenergic antagonists and 5-alpha reductase inhibitors represents optimal treatment of men with moderate-to-severe symptoms and enlarged prostates (≥30 mL).
Related Concept Videos
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Hypertension IV: Drug Therapy and Lifestyle Modifications
Urinary Tract Calculi III: Medical Management
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

